DNA X, Inc.
SONM
$3.94
-$0.54-12.07%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | 44.90% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | 44.90% | |||
| Cost of Revenue | -- | 39.18% | |||
| Gross Profit | -- | 114.91% | |||
| SG&A Expenses | -330.72% | -15.79% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -341.59% | 12.68% | |||
| Operating Income | 217.11% | 40.88% | |||
| Income Before Tax | 174.07% | 36.44% | |||
| Income Tax Expenses | -- | -35.25% | |||
| Earnings from Continuing Operations | 180.27% | 36.41% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -86.98% | 36.41% | |||
| EBIT | 217.11% | 40.88% | |||
| EBITDA | 303.34% | 48.98% | |||
| EPS Basic | -95.72% | 65.89% | |||
| Normalized Basic EPS | 261.01% | 62.89% | |||
| EPS Diluted | -95.52% | 66.03% | |||
| Normalized Diluted EPS | 261.01% | 62.89% | |||
| Average Basic Shares Outstanding | -26.62% | 86.39% | |||
| Average Diluted Shares Outstanding | -26.62% | 86.39% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||